Janus Henderson Group plc 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 3:15 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 3,137,087 6.000% | 43,791 (+1.42%) | Filing |
| 2024-02-13 10:56 am Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 3,093,296 7.200% | 1,627,029 (+110.96%) | Filing |
| 2023-02-09 09:07 am Sale | 2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 1,466,267 4.500% | -181,656 (-11.02%) | Filing |
| 2022-02-11 3:19 pm Purchase | 2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | JANUS HENDERSON GROUP PLC JHG | 1,647,923 5.100% | 1,647,923 (New Position) | Filing |